Akero Therapeutics Shares Significant Efruxifermin Trial Findings
Akero Therapeutics Highlights Efruxifermin's Impact on Fibrosis In an exciting development for patients battling serious metabolic diseases, Akero Therapeutics, Inc. (NASDAQ: AKRO) has shared promising results from the Phase 2b SYMMETRY trial, which investigates the effectiveness of efruxifermin (EFX) for treating compensated cirrhosis caused by metabolic...
Continue Reading